ADMA Biologics (NASDAQ:ADMA) Issues Quarterly Earnings Results, Meets Expectations

Key Points

• ADMA reported Q1 EPS of $0.19 (in line with estimates) and showed strong profitability and cash generation — adjusted net income rose 22% YoY, gross margin expanded to 71%, adjusted EBITDA was $59.7M, and operating cash flow was about $58M with pro forma net leverage below 0.5x.
• Operationally, growth was driven by ASCENIV (record demand, +28% YoY and a recent pediatric label expansion), while BIVIGAM sales fell ~54% YoY due to aggressive discounting and distributor shifts, contributing to a revenue miss ($114.5M vs. ~$140M estimate) and a narrowed outlook with 2026 revenue guidance of $530–$560M.
• Shares traded lower amid mixed analyst views (consensus "Moderate Buy") and heightened risk as multiple securities‑law firms opened investigations, increasing potential litigation and investor uncertainty.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported $0.19 earnings per share for the quarter, hitting analysts' consensus estimates of $0.19, FiscalAI reports. The firm had revenue of $114.49 million during the quarter, compared to the consensus estimate of $139.98 million. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.

Here are the key takeaways from ADMA Biologics' conference call:

• Company reported strong profitability and cash generation in Q1 — adjusted net income rose 22% YoY, gross margin expanded to 71%, adjusted EBITDA was $59.7M, and operating cash flow was ~$58M with pro forma net leverage below 0.5x.
• ASCENIV is the operational growth engine with record demand and utilization (revenue +28% YoY), expanding prescriber adoption, and a recent pediatric label expansion that the company cites as a key catalyst.
• BIVIGAM sales fell ~54% YoY due to aggressive discounting from new entrants and distributor inventory/ordering shifts; management calls the disruption transitory but it materially pressured Q1 top line.
• Management narrowed visibility and withdrew longer-term guidance amid competitive uncertainty, setting 2026 revenue to $530M–$560M and raising near-term R&D/SG&A to support the pipeline, which could weigh on margins if competition persists.
• Pipeline progress — ADMA plans a Pre‑IND for SG‑001 this year, will present preclinical data soon, and estimates a potential $300M–$500M peak market while leveraging yield‑enhanced manufacturing and diversified plasma sourcing.

ADMA Biologics Trading Down 1.7%

NASDAQ:ADMA traded down $0.17 during trading hours on Wednesday, hitting $10.08. The company had a trading volume of 12,591,621 shares, compared to its average volume of 5,206,077. The company has a market capitalization of $2.40 billion, a PE ratio of 16.80 and a beta of 0.83. The stock has a 50-day moving average price of $12.39 and a 200 day moving average price of $15.54. ADMA Biologics has a 52 week low of $7.21 and a 52 week high of $23.98. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on ADMA shares. Wall Street Zen cut ADMA Biologics from a "buy" rating to a "hold" rating in a report on Monday. Zacks Research lowered ADMA Biologics from a "strong-buy" rating to a "hold" rating in a report on Monday, April 27th. Mizuho dropped their price target on ADMA Biologics from $30.00 to $24.00 and set an "outperform" rating on the stock in a report on Monday, April 13th. Canaccord Genuity Group began coverage on ADMA Biologics in a research report on Monday, April 20th. They issued a "buy" rating and a $21.00 price objective on the stock. Finally, Cantor Fitzgerald restated a "neutral" rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $25.67.

Insider Activity at ADMA Biologics

In other news, Director Steve Elms acquired 7,000 shares of the business's stock in a transaction on Thursday, March 5th. The shares were acquired at an average cost of $15.67 per share, with a total value of $109,690.00. Following the transaction, the director owned 2,038,730 shares in the company, valued at $31,946,899.10. The trade was a 0.34% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of ADMA Biologics stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the sale, the chief operating officer owned 466,600 shares in the company, valued at $7,292,958. This represents a 2.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 3.90% of the company's stock.

Institutional Investors Weigh In On ADMA Biologics

Institutional investors have recently modified their holdings of the business. Summit Securities Group LLC bought a new stake in ADMA Biologics in the 4th quarter worth about $29,000. iSAM Funds UK Ltd bought a new stake in shares of ADMA Biologics in the third quarter worth approximately $34,000. EverSource Wealth Advisors LLC raised its stake in ADMA Biologics by 385.8% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company's stock valued at $50,000 after buying an additional 2,180 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in shares of ADMA Biologics by 28.9% in the 2nd quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company's stock worth $57,000 after purchasing an additional 700 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new stake in shares of ADMA Biologics in the 4th quarter worth $72,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: FDA label expansion broadens pediatric market for ASCENIV, increasing addressable patients and long‑term upside for product sales. ADMA Biologics Gains FDA Approval for Expanded ASCENIV Label
• Positive Sentiment: Q1 operational strength: ASCENIV revenue grew ~28% Y/Y, adjusted net income and adjusted EBITDA both rose, and cash from operations was strong — evidence of durable demand and near-term cash generation. ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
• Neutral Sentiment: Q1 reported EPS of $0.19 matched consensus but total revenue of $114.5M missed street estimates (~$140M), a mixed print that limited upside despite profitability metrics. View Press Release
• Negative Sentiment: ADMA lowered FY‑2026 revenue guidance to $530M–$560M vs. consensus ~ $625M and withdrew long‑term guidance, signaling a weaker top‑line outlook and creating near‑term downside risk to the stock. ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
• Negative Sentiment: Multiple securities‑law firms announced investigations and encouraged investors to contact them over alleged misleading disclosures and the recent share decline — heightening litigation risk and investor uncertainty. ADMA Investor News - Rosen Law Firm Investigation BFA Law Investigation Notice

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.